Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2026)
Tango Therapeutics' (TNGX) quarterly Income from Continuing Operations came in at 45514000.0 in Q1 2026, down 14.14% year-on-year from 53008828.32 in Q1 2025, and down 17.46% quarter-over-quarter from 38748000.0 in Q4 2025.
Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tango Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45514000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 14.14% year-over-year to 45514000.0 in Q1 2026; TTM through Mar 2026 was 107231000.0, a 18.93% increase from a year earlier, with the FY2025 full-year figure at 101593000.0, up 22.03% from the prior year.
- Income from Continuing Operations retreated to 45514000.0 in Q1 2026 per TNGX's latest filing, from 38748000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15884000.0 in Q3 2025 and bottomed at 45514000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 29106000.0 (2022), against an average of 28669235.29.
- Across the five-year window, Income from Continuing Operations slumped 453.26% in 2022 and surged 154.46% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 29106000.0 in 2022, then fell by 5.58% to 30729000.0 in 2023, then fell by 22.59% to 37670000.0 in 2024, then fell by 2.86% to 38748000.0 in 2025, then slipped by 17.46% to 45514000.0 in 2026.
- Per Business Quant, the three latest TNGX Income from Continuing Operations figures stand at 45514000.0 (Q1 2026), 38748000.0 (Q4 2025), and 15884000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Tango Therapeutics | 3.94 Bn | 3.78 Bn | - | -45.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.51 Mn |
| Dec 31, 2025 | -38.75 Mn |
| Sep 30, 2025 | 15.88 Mn |
| Jun 30, 2025 | -38.85 Mn |
| Mar 31, 2025 | -39.88 Mn |
| Dec 31, 2024 | -37.67 Mn |
| Sep 30, 2024 | -29.17 Mn |
| Jun 30, 2024 | -25.55 Mn |
| Mar 31, 2024 | -37.91 Mn |
| Dec 31, 2023 | -30.73 Mn |
| Sep 30, 2023 | -22.26 Mn |
| Jun 30, 2023 | -20.75 Mn |
| Mar 31, 2023 | -28.01 Mn |
| Dec 31, 2022 | -29.11 Mn |
| Sep 30, 2022 | -29.05 Mn |
| Jun 30, 2022 | -24.86 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -22.05 Mn |
| Sep 30, 2021 | -19.59 Mn |
| Jun 30, 2021 | -4.49 Mn |